Each to their own risk profile I suppose. As a BOT shareholder I would be 100% behind this cap raising and royalty acquisition as for me there is next to zero risk. If it sounds cocky so be it - but I believe FDA approval for SB is a given. I think this is a very business savvy move by BOT management.
The acne debacle is not the same as FDA SB approval. Whereas acne was a manufacturing cockup, for SB the management team have scrutinised the study before submitting, have had a mid cycle FDA review with no issues, and are in final discussions with FDA about labelling. Having already taken 30 or so products to market previously, I believe in the BOT management team and SB. But I fully appreciate others may be cynical/skeptical/ risk averse.
Ann: Trading Halt, page-68
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.010(2.90%) |
Mkt cap ! $642.5M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 34.0¢ | $1.005M | 2.886M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 75000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 312537 | 10 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |